This no-fault compensation mechanism helps to ensure that people in AMC-eligible countries and economies can benefit from the cutting-edge science that has delivered COVID-19 vaccines in record time,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General.
2022
我们很高兴与安达保险公司合作，该公司有能力通过其全球网络和理赔能力来支持COVAX机制。
“We are pleased to be collaborating with Chubb, which has the capabilities to support the COVAX facility through its global network and claims handling ability.
2023
世卫组织与安达保险公司的协议可提供进一步保护并增强对疫苗救生能力的信心”。
WHO’s agreement with Chubb offers further protection and confidence in the life-saving power of vaccines.”
“The No-Fault Compensation fund is a massive boost for COVAX’s goal of equitable global access to vaccines: by providing a robust, transparent and independent mechanism to settle serious adverse events it helps those in countries who might have such effects, manufacturers to roll out vaccines to countries faster, and is a key benefit for lower-income governments procuring vaccines through the Gavi COVAX AMC,” said Dr Seth Berkley, CEO of Gavi.
The COVAX no-fault compensation programme will be operationalized through its web portal (www.covaxclaims.com) by 31 March 2021, which will include resources such as the programme’s protocol, Frequently Asked Questions (FAQs) and information on how to submit an application.
Eligible individuals may apply for compensation under the programme once the portal becomes operational, even if a COVAX-distributed vaccine is administered to them before 31 March 2021.
The programme is financed initially through Gavi COVAX AMC donor funding, calculated as a levy charged on all doses of COVID-19 vaccines distributed through the COVAX Facility to the AMC eligible economies until 30 June 2022.
2028
世卫组织正在与安达保险公司一道锁定该规划的保险范围，并由安达担任主要承保方。
WHO is working with Chubb to secure insurance coverage for the programme with Chubb as lead insurer.
2029
安达保险公司董事长兼首席执行官Evan G. Greenberg说：“安达很自豪也很荣幸能与世界卫生组织及其伙伴就这个极其重要的COVAX规划进行合作。
“Chubb is proud and honoured to work with the World Health Organization and its partners on the critically important COVAX programme,” said Evan G. Greenberg, Chairman and Chief Executive Officer of Chubb.
“The COVID-19 pandemic has had a devastating effect on people and economies around the globe, and the development and deployment of efficacious vaccines is a crucial step toward ending this crisis.